Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials
Anemia is a common problem when patients present with cancer, and it can worsen during treatment. Anemia can directly impact the cognitive and physical quality of life and may impair fitness for oncological therapy. The most common cause of anemia is iron deficiency. Newer intravenous (IV) iron form...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/9/569 |
| _version_ | 1797580647375568896 |
|---|---|
| author | Jayne Lim Michael Auerbach Beth MacLean Annas Al-Sharea Toby Richards |
| author_facet | Jayne Lim Michael Auerbach Beth MacLean Annas Al-Sharea Toby Richards |
| author_sort | Jayne Lim |
| collection | DOAJ |
| description | Anemia is a common problem when patients present with cancer, and it can worsen during treatment. Anemia can directly impact the cognitive and physical quality of life and may impair fitness for oncological therapy. The most common cause of anemia is iron deficiency. Newer intravenous (IV) iron formulations offer a safe and rapidly effective treatment option. We performed a systematic mapping review of randomized controlled trials (RCTs) evaluating intravenous iron therapy in patients with cancer and anemia and their outcomes. A total of 23 RCTs were identified. The median number of patients enrolled was 104 (IQR: 60–134). A total of 5 were focused on surgical outcomes (4 preoperative, 1 postoperative), and 15 were in adjuvant therapies for a variety of tumor types (breast, colorectal, lung, gynecological, myeloid, and lymphomas), 10 of which were in combination with erythropoietin-stimulating agents (ESAs) therapy, 2 in radiotherapy, and 1 in palliative care. Overall, the studies reported that the use of IV iron increased hemoglobin concentration and decreased transfusion rates during different cancer treatment regimes. IV iron can be administered safely throughout the cancer treatment pathway from primary surgery to the palliative setting. More studies are needed to demonstrate net clinical outcomes. |
| first_indexed | 2024-03-10T22:52:52Z |
| format | Article |
| id | doaj.art-0c1077848a444edcb8c2249fbd7265c5 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T22:52:52Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-0c1077848a444edcb8c2249fbd7265c52023-11-19T10:10:38ZengMDPI AGCurrent Oncology1198-00521718-77292023-08-013097836785110.3390/curroncol30090569Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled TrialsJayne Lim0Michael Auerbach1Beth MacLean2Annas Al-Sharea3Toby Richards4School of Medicine, University of Western Australia, Perth, WA 6009, AustraliaDepartment of Medicine, Georgetown University, Washington, DC 20007, USASchool of Medicine, University of Western Australia, Perth, WA 6009, AustraliaSchool of Medicine, University of Western Australia, Perth, WA 6009, AustraliaSchool of Medicine, University of Western Australia, Perth, WA 6009, AustraliaAnemia is a common problem when patients present with cancer, and it can worsen during treatment. Anemia can directly impact the cognitive and physical quality of life and may impair fitness for oncological therapy. The most common cause of anemia is iron deficiency. Newer intravenous (IV) iron formulations offer a safe and rapidly effective treatment option. We performed a systematic mapping review of randomized controlled trials (RCTs) evaluating intravenous iron therapy in patients with cancer and anemia and their outcomes. A total of 23 RCTs were identified. The median number of patients enrolled was 104 (IQR: 60–134). A total of 5 were focused on surgical outcomes (4 preoperative, 1 postoperative), and 15 were in adjuvant therapies for a variety of tumor types (breast, colorectal, lung, gynecological, myeloid, and lymphomas), 10 of which were in combination with erythropoietin-stimulating agents (ESAs) therapy, 2 in radiotherapy, and 1 in palliative care. Overall, the studies reported that the use of IV iron increased hemoglobin concentration and decreased transfusion rates during different cancer treatment regimes. IV iron can be administered safely throughout the cancer treatment pathway from primary surgery to the palliative setting. More studies are needed to demonstrate net clinical outcomes.https://www.mdpi.com/1718-7729/30/9/569anemiaoncologymappingrandomized controlled trials |
| spellingShingle | Jayne Lim Michael Auerbach Beth MacLean Annas Al-Sharea Toby Richards Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials Current Oncology anemia oncology mapping randomized controlled trials |
| title | Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials |
| title_full | Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials |
| title_fullStr | Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials |
| title_full_unstemmed | Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials |
| title_short | Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials |
| title_sort | intravenous iron therapy to treat anemia in oncology a mapping review of randomized controlled trials |
| topic | anemia oncology mapping randomized controlled trials |
| url | https://www.mdpi.com/1718-7729/30/9/569 |
| work_keys_str_mv | AT jaynelim intravenousirontherapytotreatanemiainoncologyamappingreviewofrandomizedcontrolledtrials AT michaelauerbach intravenousirontherapytotreatanemiainoncologyamappingreviewofrandomizedcontrolledtrials AT bethmaclean intravenousirontherapytotreatanemiainoncologyamappingreviewofrandomizedcontrolledtrials AT annasalsharea intravenousirontherapytotreatanemiainoncologyamappingreviewofrandomizedcontrolledtrials AT tobyrichards intravenousirontherapytotreatanemiainoncologyamappingreviewofrandomizedcontrolledtrials |